PE20120488A1 - Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo - Google Patents

Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo

Info

Publication number
PE20120488A1
PE20120488A1 PE2011002080A PE2011002080A PE20120488A1 PE 20120488 A1 PE20120488 A1 PE 20120488A1 PE 2011002080 A PE2011002080 A PE 2011002080A PE 2011002080 A PE2011002080 A PE 2011002080A PE 20120488 A1 PE20120488 A1 PE 20120488A1
Authority
PE
Peru
Prior art keywords
pyrrolidin
benzofuran
dihydro
ilaminoacilo
alkyl
Prior art date
Application number
PE2011002080A
Other languages
English (en)
Inventor
Josep Lluis Falco
Albert Palomer
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of PE20120488A1 publication Critical patent/PE20120488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE 1-(2-ALQUIL-2,3-DIHIDRO-BENZOFURAN-4-IL)-PIRROLIDIN-3-ILAMINOACILO TAL COMO N-((3S)-1-(7-FLUORO-2-METIL-2,3-DIHIDROBENZOFURAN-4-IL)-PIRROLIDIN-3-IL)ACETAMIDA, 2,2,2-TRIFLUORO-N-((3S)-1-(7-FLUORO-2-METIL-2,3-DIHIDRO-BENZOFURAN-4-IL)-PIRROLIDIN-3-IL)ACETAMIDA, N-((3S)-1-(2-METIL-2,3-DIHIDRO-BENZOFURAN-4-IL)-PIRROLIDIN-3-IL)ACETAMIDA, 1-ETIL-3-((3S)-1-(7-FLUORO-2-METIL-2,3-DIHIDRO-BENZOFURAN-4-IL)-PIRROLIDIN-3-IL)UREA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE LOS RECEPTORES DE MELATONINA Y SON UTILES EN EL TRATAMIENTO DE DEPRESION, ESTRES, ANSIEDAD, ESQUIZOFRENIA, ENTRE OTROS
PE2011002080A 2009-06-15 2010-06-10 Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo PE20120488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09162731A EP2266975A1 (en) 2009-06-15 2009-06-15 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds

Publications (1)

Publication Number Publication Date
PE20120488A1 true PE20120488A1 (es) 2012-04-27

Family

ID=41136948

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002080A PE20120488A1 (es) 2009-06-15 2010-06-10 Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo

Country Status (15)

Country Link
US (1) US20120088809A1 (es)
EP (2) EP2266975A1 (es)
JP (1) JP2012530097A (es)
KR (1) KR20120036840A (es)
CN (1) CN102803253A (es)
AR (1) AR076772A1 (es)
AU (1) AU2010261961A1 (es)
CA (1) CA2762304A1 (es)
CL (1) CL2011003165A1 (es)
MX (1) MX2011013073A (es)
PE (1) PE20120488A1 (es)
RU (1) RU2012101227A (es)
TW (1) TW201102381A (es)
UY (1) UY32654A (es)
WO (1) WO2010145989A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160223567A1 (en) 2013-09-09 2016-08-04 Chu Sainte-Justine Method of treating and prognosing scoliotic patient subgroups
EP3438089A1 (en) 2013-12-18 2019-02-06 Monsanto Technology LLC Processes for the diazotization of 2,5-dichloroanilines
CN116253704A (zh) * 2021-12-10 2023-06-13 中国科学院昆明植物研究所 Paeoveitol D衍生物及其药物组合物和其制备方法与其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002392A1 (en) * 1999-06-30 2001-01-11 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
MX2008014840A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.

Also Published As

Publication number Publication date
AU2010261961A1 (en) 2011-12-08
MX2011013073A (es) 2012-02-28
KR20120036840A (ko) 2012-04-18
EP2443108A1 (en) 2012-04-25
AR076772A1 (es) 2011-07-06
US20120088809A1 (en) 2012-04-12
UY32654A (es) 2010-11-30
CL2011003165A1 (es) 2012-07-06
CA2762304A1 (en) 2010-12-23
TW201102381A (en) 2011-01-16
CN102803253A (zh) 2012-11-28
EP2266975A1 (en) 2010-12-29
RU2012101227A (ru) 2013-07-27
WO2010145989A1 (en) 2010-12-23
JP2012530097A (ja) 2012-11-29

Similar Documents

Publication Publication Date Title
ECSP11010898A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP13012499A (es) Nuevos compuestos
ECSP12012083A (es) Pirrolidina-2-carboxamidas sustituidas
PL410258A1 (pl) Weterynaryjne doustne kompozycje przeciwpasożytnicze obejmujące działające systemowo substancje czynne, sposoby i zastosowania je obejmujące
CO6321232A2 (es) Compuesto de tropano como inhibidores de hsp90
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
PE20090772A1 (es) Derivados de bencimidazol
UY31189A1 (es) Compuestos heterocíclicos
CO6311077A2 (es) Derivados de 1-(4-hidroxi-fenil)-1h-indol como ligandos novedosos de receptor de estrógeno
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
CO6400172A2 (es) C5ar antagonistas
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
UY32238A (es) Agonistas de los receptores de la melanocortina
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
PE20151073A1 (es) Piridina-2-amidas utiles como agonistas de cb2
GT200700096A (es) Compuestos de pirazolina
PE20150709A1 (es) Benzamidas
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR20110269A (es) Lactamas como inhibidores de beta secretasa
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
PE20090549A1 (es) Derivados de imidazolidinona con actividad sobre lxr-alfa y lxr-beta
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal